Publications (9) Rosa María Álvarez Gil publications

filter_list

2025

  1. Effectiveness of catch-up and at-birth nirsevimab immunisation against RSV hospital admission in the first year of life: a population-based case–control study, Spain, 2023/24 season

    Eurosurveillance, Vol. 30, Núm. 5

  2. Infants needed to immunise with nirsevimab to prevent one RSV hospitalisation, Spain, 2023/24 season

    Eurosurveillance, Vol. 30, Núm. 13

2024

  1. Assessment of effectiveness and impact of universal prophylaxis with nirsevimab for prevention of hospitalizations due to respiratory syncytial virus in infants. The NIRSE-GAL study protocol

    Human Vaccines and Immunotherapeutics, Vol. 20, Núm. 1

  2. Effectiveness and impact of universal prophylaxis with nirsevimab in infants against hospitalisation for respiratory syncytial virus in Galicia, Spain: initial results of a population-based longitudinal study

    The Lancet Infectious Diseases, Vol. 24, Núm. 8, pp. 817-828

  3. Short- and mid-term morbidity and primary-care burden due to infant respiratory syncytial virus infection: A Spanish 6-year population-based longitudinal study

    Pediatric Allergy and Immunology, Vol. 35, Núm. 5

2009

  1. Diagnóstico rápido de enfermedades de transmisión sexual en atención primaria

    Cadernos de atención primaria, Vol. 16, Núm. 1, pp. 44-47

2005

  1. Agradecimientos

    Pasarela Fortuny: jóvenes diseñadores, Granada 20 de mayo de 2005

  2. Complementos

    Pasarela Fortuny: jóvenes diseñadores, Granada 20 de mayo de 2005

  3. Curriculums

    Pasarela Fortuny: jóvenes diseñadores, Granada 20 de mayo de 2005